López-Rodríguez M L, Murcia M, Benhamú B, Olivella M, Campillo M, Pardo L
Unitat de Bioestadística, Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain.
J Comput Aided Mol Des. 2001 Nov;15(11):1025-33. doi: 10.1023/a:1014895611874.
A computational model of the transmembrane domain of the human 5-HT4 receptorcomplexed with the GR113808 antagonist was constructed from the crystal structure of rhodopsin and the putative residues of the ligand-binding site, experimentally determined by site-directed mutagenesis. The recognition mode of GR113808 consist of: (i) the ionic interaction between the protonated amine and Asp3.32; (ii) the hydrogen bond between the carbonylic oxygen and Ser5.43; (iii) the hydrogen bond between the ether oxygen and Asn6.55; (iv) the hydrogen bond between the C-H groups adjacent to the protonated piperidine nitrogen and the pi electrons of Phe6.51; and (v) the pi-sigma aromatic-aromatic interaction between the indole ring and Phe6.52. This computational model offers structural indications about the role of Asp3.32, Ser5.43, Phe6.51, Phe6.52, and Asn6.55 in the experimental binding affinities. Asp3.32Asn mutation does not affect the binding of GR113808 because the loss of binding affinity from an ion pair to a charged hydrogen bond is compensated by the larger energetical penalty of Asp to disrupt its side chain environment in the ligand-free form, and the larger interaction between Phe6.51 and the piperidine ring of the ligand in the mutant receptor. In the Phe6.52Val mutant the indole ring of the ligand replaces the interaction with Phe6.52 by a similarly intense interaction with Tyr5.38, with no significant effect in the binding of GR113808. The mutation of Asn6.55 to Leu replaces the hydrogen bond of the ether oxygen of the ligand from Asn6.55 to Cys5.42, with a decrease of binding affinity that approximately equals the free energy difference between the SH...O and NH...O hydrogen bonds. Because these residues are also present in the other members of the neurotransmitter family of G protein-coupled receptors, these findings will also serve for our understanding of the binding of related ligands to their cognate receptors.
基于视紫红质的晶体结构和通过定点诱变实验确定的配体结合位点的推定残基,构建了与GR113808拮抗剂复合的人5-HT4受体跨膜结构域的计算模型。GR113808的识别模式包括:(i) 质子化胺与Asp3.32之间的离子相互作用;(ii) 羰基氧与Ser5.43之间的氢键;(iii) 醚氧与Asn6.55之间的氢键;(iv) 与质子化哌啶氮相邻的C-H基团与Phe6.51的π电子之间的氢键;以及(v) 吲哚环与Phe6.52之间的π-σ芳香-芳香相互作用。该计算模型提供了关于Asp3.32、Ser5.43、Phe6.51、Phe6.52和Asn6.55在实验结合亲和力中作用的结构指示。Asp3.32Asn突变不影响GR113808的结合,因为离子对到带电氢键的结合亲和力丧失被Asp以无配体形式破坏其侧链环境的更大能量代价以及突变受体中Phe6.51与配体哌啶环之间更大的相互作用所补偿。在Phe6.52Val突变体中,配体的吲哚环通过与Tyr5.38的类似强烈相互作用取代了与Phe6.52的相互作用,对GR113808的结合没有显著影响。Asn6.55突变为Leu将配体醚氧的氢键从Asn6.55替换为Cys5.42,结合亲和力降低,其降低程度近似等于SH...O和NH...O氢键之间的自由能差。由于这些残基也存在于G蛋白偶联受体神经递质家族的其他成员中,这些发现也将有助于我们理解相关配体与其同源受体的结合。